Table 1.
CLEAR registry patient characteristics.
| Class 1 (n = 37) | Class 2 (n = 33) | p value | |
|---|---|---|---|
| Gender: | |||
| Female, n (%) | 13 (35%) | 24 (73%) | 0.002a |
| Male, n (%) | 24 (65%) | 9 (27%) | |
|
| |||
| Age at diagnosis (yrs) | |||
| Mean | 60.5 | 62.7 | 0.52b |
| Median | 62 | 63 | |
| Range | 29–84 | 31–87 | |
|
| |||
| Ciliary body involvement, n (%) | 15 (41%) | 12 (36%) | 0.81a |
|
| |||
| Tumor diameter (mm) | |||
| ≤10 (% of row) | 11 (73%) | 4 (27%) | |
| >10 to ≤15 (% of row) | 15 (58%) | 11 (42%) | |
| >15 (% of row) | 11 (38%) | 18 (62%) | |
| Mean (SD) | 12.8 (1.84) | 15.64 (4.95) | 0.02b |
|
| |||
| Tumor thickness (mm) | |||
| ≤3 (% of row) | 9 (69%) | 4 (31%) | |
| >3 to ≤8 (% of row) | 18 (54%) | 15 (46%) | |
| >8 (% of row) | 10 (42%) | 14 (58%) | |
| Mean (SD) | 5.89 (3.34) | 7.02 (3.39) | 0.16b |
|
| |||
| Treatment type | |||
| Enucleation | 9 (24%) | 17 (52%) | 0.026a |
| Plaque radiotherapy | 23 (62%) | 11 (33%) | 0.019a |
| Proton beam | 3 (8%) | 1 (3%) | 0.61a |
| TTT | 0 (0%) | 1 (3%) | 0.47a |
| None | 2 (5%) | 3 (9%) | 0.62a |
|
| |||
| Follow-up (years) | |||
| Mean | 2.7 | 2.5 | 0.62b |
| Median | 2.6 | 2.0 | |
|
| |||
| Metastatic events, n (%) | 2 (5%) | 12 (36%) | 0.002a |
|
| |||
| High-intensity management ∗ | 7 (19%) | 33 (100%) | 2.1 × 10−13 a |
|
| |||
| Referrals | 4 (11%) | 11 (33%) | 0.04a |
| Medical oncology | 4 (11%) | 6 (18%) | |
| Clinical trials | 0 (0%) | 8 (24%) | |
|
| |||
| Systemic adjuvant therapy | 0 (0%) | 4 (12%) | 0.04a |
TTT: transpupillary thermotherapy.
aFisher's exact test; bStudent's t-test.
∗Liver function tests and/or imaging every 3–6 months.